Maintenance Of Clinical Response And Remission In Adults With Moderately To Severely Active Ulcerative Colitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis. 9 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
9
Active US patents
54/100
Avg vulnerability
—
Annual revenue covered

Originators in Maintenance Of Clinical Response And Remission In Adults With Moderately To Severely Active Ulcerative Colitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis. Each bar = one year. Y-axis scaled to peak year (7 patents).

1
29
1
30
7
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Velsipity
Etrasimod Arginine
 Pfizer Inc. 9 54 — 2029-07-22

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9126932 Velsipity method of use 76 2029-07-22
12156866 Velsipity method of use 75 2036-01-06
12377071 Velsipity method of use 75 2036-01-06
11884626 Velsipity method of use 75 2036-06-21
11007175 Velsipity method of use 70 2036-01-06
10676435 Velsipity method of use 70 2036-06-21
8580841 Velsipity composition of matter 18 2030-03-05
11091435 Velsipity composition of matter 12 2036-06-21
10301262 Velsipity composition of matter 12 2036-06-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11091435 Velsipity composition of matter 12 2036-06-21
10301262 Velsipity composition of matter 12 2036-06-21
8580841 Velsipity composition of matter 18 2030-03-05
10676435 Velsipity method of use 70 2036-06-21
11007175 Velsipity method of use 70 2036-01-06
11884626 Velsipity method of use 75 2036-06-21
12156866 Velsipity method of use 75 2036-01-06
12377071 Velsipity method of use 75 2036-01-06
9126932 Velsipity method of use 76 2029-07-22

Related